MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iTeos Therapeutics, Inc. - Common Stock (NQ:ITOS)

10.15 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 10.15
Bid (Size) 10.17 (999)
Ask (Size) 10.22 (10)
Prev. Close 10.15
Today's Range 10.15 - 10.15
52wk Range 4.800 - 11.35
Shares Outstanding 35,763,742
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS
From Kahn Swick & Foti, LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, VBTX, TTNP on Behalf of Shareholders July 31, 2025
From Halper Sadeh LLC
Via GlobeNewswire

Performance

YTD
+28.5%
+28.5%
1 Month
N/A
N/A
3 Month
+1.8%
+1.8%
6 Month
+70.0%
+70.0%
1 Year
-3.3%
-3.3%

More News

Read More
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, ZIMV, SPTN on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: iTeos Therapeutics, Inc. (Nasdaq - ITOS), ZimVie Inc. (Nasdaq - ZIMV), PharmChem, Inc. (OTC - PCHM), NV5 Global, Inc. (Nasdaq - NVEE)
From Brodsky & Smith LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, CIO, SNV on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, ZIMV, TASK, OLO on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
From iTeos Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’
Via Stocktwits
Topics Intellectual Property
These stocks are gapping in today's session
Via Chartmill
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
iTeos Therapeutics Announces Its Intention to Wind Down Operations
From iTeos Therapeutics Inc.
Via GlobeNewswire
This Wayfair Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday
Via Benzinga
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile
Via Benzinga
iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish
Via Stocktwits
Topics Government
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
From iTeos Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is iTeos Therapeutics, Inc. - Common Stock publicly traded?
Yes, iTeos Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does iTeos Therapeutics, Inc. - Common Stock trade on?
iTeos Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for iTeos Therapeutics, Inc. - Common Stock?
The ticker symbol for iTeos Therapeutics, Inc. - Common Stock is ITOS on the Nasdaq Stock Market
What is the current price of iTeos Therapeutics, Inc. - Common Stock?
The current price of iTeos Therapeutics, Inc. - Common Stock is 10.15
When was iTeos Therapeutics, Inc. - Common Stock last traded?
The last trade of iTeos Therapeutics, Inc. - Common Stock was at 08/28/25 04:00 PM ET
What is the market capitalization of iTeos Therapeutics, Inc. - Common Stock?
The market capitalization of iTeos Therapeutics, Inc. - Common Stock is 363.00M
How many shares of iTeos Therapeutics, Inc. - Common Stock are outstanding?
iTeos Therapeutics, Inc. - Common Stock has 363M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story